Balancia500 mg

Citicoline sodium is used, under medical guidance, for:

• Adjunctive management of acute ischaemic stroke and support of neurological and functional recovery in the post-stroke period
• Cognitive, sensory, and motor neurological disorders of degenerative and vascular origin, including chronic cerebral ischaemia with memory impairment, reduced initiative, and difficulty with daily activities
• Traumatic brain injury, where it may help reduce the duration of post-traumatic impaired consciousness and the severity of neurological symptoms
• Adjunctive support in Parkinson's disease and age-related cognitive decline, in some clinical settings

Clinical trial evidence for citicoline is mixed - some studies show meaningful benefit, particularly for post-stroke functional and cognitive recovery, while other large trials in acute stroke and traumatic brain injury have not shown a clear benefit, so it should be used as part of an individualized treatment plan discussed with a doctor, rather than viewed as a proven cure for any of these conditions.

Contains Balancia 500 mg as the active ingredient, available as oral tablets (commonly 500 mg and 1000 mg) and oral solution, and as an injectable solution for intravenous or intramuscular use.

Citicoline (cytidine diphosphate-choline, CDP-choline) is a naturally occurring compound involved in the production of phosphatidylcholine, an essential building block of nerve cell membranes, and is used as a neuroprotective and nootropic agent to support brain function and recovery after stroke, traumatic brain injury, and in certain chronic cognitive conditions. It is available as oral tablets or solution, and as an intravenous or intramuscular injection for use in acute settings under medical supervision. While generally well tolerated with a favourable safety profile, the strength of clinical evidence for its benefit varies by condition and has been inconsistent across large clinical trials.

Therapeutic Class: Neuroprotective / Nootropic Agent

After ingestion or injection, citicoline is rapidly broken down into its two components, cytidine and choline, which enter the brain separately and are then resynthesized into citicoline within brain cells, where it serves as a precursor for phosphatidylcholine synthesis. Oral citicoline reaches peak plasma levels within 1-2 hours, while intravenous administration provides near-immediate availability. Citicoline is believed to help stabilize cell membranes and reduce the extent of tissue damage in ischaemic or injured brain tissue in preclinical models, though translation of this benefit into consistent clinical outcomes has been variable across studies.

• Oral tablets or solution may be taken with or without food
• Injectable forms are administered by a qualified healthcare professional, typically in a hospital setting, by slow intravenous injection, infusion, or intramuscular injection
• Do not discontinue without consulting your doctor, particularly if being used for an ongoing chronic neurological condition
• Adhere strictly to the prescribed duration of therapy for your specific condition

The following should be assessed by a healthcare professional before combining with citicoline:

• Anticholinergic medicines (used for conditions such as asthma or overactive bladder): may counteract citicoline's cholinergic effects, potentially reducing its intended cognitive or neurological benefit.
• Levodopa (used for Parkinson's disease): citicoline may enhance the effects of levodopa; this combination is sometimes used deliberately under specialist guidance, but should be monitored for increased levodopa-related effects.
• Other central nervous system-active medicines: theoretical potential for additive effects; discuss any other neurological or psychiatric medicines with your doctor.

Common side effects

• Headache
• Dizziness or vertigo
• Gastrointestinal upset, including stomach discomfort and diarrhoea
• Restlessness

Less common side effects

Citicoline is generally well tolerated, with side effects usually mild and often improving as the body adjusts to the medicine.

Serious effects (seek medical attention)

• Signs of a severe allergic reaction: rash, swelling, difficulty breathing (rare)

Pregnancy

Information regarding safety and efficacy of citicoline in pregnancy at doses above typical nutritional/dietary intake is lacking; use during pregnancy should only occur if a doctor determines it is necessary, weighing the potential benefit against limited safety data.

Breastfeeding

Data on citicoline use during breastfeeding at treatment doses are not well documented; use should be discussed with a healthcare professional.

• Evidence for benefit varies by condition and severity - discuss realistic expectations with your doctor, since large clinical trials have shown inconsistent results for some indications (such as acute ischaemic stroke and traumatic brain injury), even though citicoline remains widely used, particularly in some countries, for post-stroke and cognitive support.
• Citicoline is generally well tolerated, but do not exceed the dose or duration prescribed by your doctor.
• Long-term use should be monitored by a healthcare professional to assess ongoing benefit and tolerability.
• Injectable forms require administration by a trained healthcare professional in an appropriate clinical setting.

Citicoline has a wide margin of safety in reported clinical use, and significant toxicity from overdose has not been well characterized; excessive doses may be expected to cause more pronounced versions of known side effects, such as headache, dizziness, or gastrointestinal upset. Suspected significant overdose should be evaluated by a healthcare professional; treatment is generally supportive.

Store oral tablets and solution at room temperature, protected from moisture and light. Store injectable ampoules as directed on the product label, generally at room temperature, protected from light.

• Elderly: Commonly used for age-related cognitive decline and vascular cognitive impairment; no specific dose adjustment is generally required based on age alone.
• Renal or hepatic impairment: Limited specific dosing data are available; use with caution and under medical guidance.
• Children: Used in some settings for traumatic brain injury or specific neurological indications under specialist paediatric guidance, with dosing individualized to the child's age and condition.

Duration depends on the indication and clinical response - acute stroke or traumatic brain injury treatment is typically given for a defined period during the acute and early recovery phase, while use for chronic cognitive or neurological support may continue longer-term under a doctor's ongoing assessment of benefit.

Drug Class: Cytidine diphosphate-choline (CDP-choline), a phospholipid precursor

Citicoline provides the building blocks (cytidine and choline) needed to synthesize phosphatidylcholine, a key structural component of neuronal cell membranes, supporting membrane repair and stability in damaged or stressed brain tissue. It is also believed to increase levels of certain neurotransmitters in the central nervous system and to have a neuroprotective effect against tissue damage following ischaemia (reduced blood flow) or injury, which together underlie its proposed roles in stroke recovery, traumatic brain injury, and cognitive support.

Citicoline has been used in some paediatric settings, including traumatic brain injury, under specialist guidance, with dosing individualized to the child's age, weight, and clinical condition; established paediatric dosing recommendations are more limited than for adult use.